Patents by Inventor Ronald Vogel
Ronald Vogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7468181Abstract: The invention relates to methods and means for the production of adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: April 24, 2003Date of Patent: December 23, 2008Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Publication number: 20080206837Abstract: Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B-55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: ApplicationFiled: September 5, 2007Publication date: August 28, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Publication number: 20080199917Abstract: The invention relates to methods and means for producing adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: ApplicationFiled: May 7, 2007Publication date: August 21, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Publication number: 20080199433Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.Type: ApplicationFiled: April 11, 2007Publication date: August 21, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, Majid Mehtali
-
Publication number: 20080171018Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: ApplicationFiled: October 29, 2007Publication date: July 17, 2008Applicant: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Publication number: 20080153083Abstract: The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.Type: ApplicationFiled: October 25, 2007Publication date: June 26, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Maria Grazia Pau, Lennart Holterman, Stefan Kostense, Menzo Jans Emco Havenga, Mieke Caroline Sprangers
-
Publication number: 20080113409Abstract: Described is a method for producing a protein of interest, the method comprising: a) providing a recombinant adenoviral vector comprising nucleic acid encoding the protein of interest under control of a promoter, wherein the adenoviral vector has deletions in a first region and in a second region of the adenovirus genome, wherein each of the first region and the second region is required for adenoviral genome replication and/or adenovirus particle formation, b) propagating the adenoviral vector in a first type of complementing cells that express proteins from the first and from the second region of the adenovirus genome so as to complement the deletions of the recombinant adenoviral vector, to obtain recombinant adenovirus particles, c) infecting a culture of a second type of complementing cells with the recombinant adenovirus particles, wherein the second type of complementing cells express protein from the first region of the adenovirus genome but not protein from the second region of the adenovirus genome,Type: ApplicationFiled: June 1, 2007Publication date: May 15, 2008Inventors: Guus Hateboer, Menzo J. E. Havenga, Ronald Vogels, Lennart Holterman
-
Patent number: 7344883Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.Type: GrantFiled: June 24, 2005Date of Patent: March 18, 2008Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, Majid Mehtali
-
Patent number: 7285265Abstract: The present invention provides methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B 55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous promoter. The invention further relates to methods and means for the production of such adenoviruses on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenovirus and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products in the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: April 24, 2003Date of Patent: October 23, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Jans Emco Havenga, David Adrianus Theodorus Maria Zuijdgeest
-
Patent number: 7270811Abstract: The invention provides a gene delivery vehicle and a gene of interest comprising at least one Ad35 element or a functional equivalent thereof, responsible for avoiding or diminishing neutralizing activity against adenoviral elements by the host to which the gene is to be delivered. A functional equivalent/homologue of an Ad35 (element) includes an adenovirus (element) which, like adenovirus 35, encounters pre-existing immunity in less than about 10% of the hosts to which it is administered for the first time, or which is capable in more than about 90% of the hosts to which it is administered of avoiding or diminishing the immune response.Type: GrantFiled: September 27, 2004Date of Patent: September 18, 2007Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Patent number: 7250293Abstract: A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary diploid human cells transformed by adenovirus E1 sequences either operatively linked on one or two DNA molecules, the sequences operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also, a cell line derived from PER.C6 that expresses functional Ad35-E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses. The cell lines can be used to produce human recombinant therapeutic proteins such as human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza, herpes simplex, rotavirus, and measles.Type: GrantFiled: October 15, 2002Date of Patent: July 31, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo Havenga, Majid Mehtali
-
Patent number: 7238528Abstract: The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect, the nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably, the virus capsid is an adenovirus capsid. Preferably, the adenovirus is a subgroup B adenovirus, such as adenovirus 16. Preferably, the tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, such as joint related diseases.Type: GrantFiled: February 20, 2004Date of Patent: July 3, 2007Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Govert Johan Schouten, Abraham Bout, Menzo Jans Emco Havenga
-
Publication number: 20070041946Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: ApplicationFiled: October 25, 2006Publication date: February 22, 2007Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Publication number: 20060183232Abstract: In the absence of substantial sequence overlap between a recombinant adenoviral vector and the genome of a packaging cell, helper-dependent E1-containing particles (HDEP) can be formed at low frequency. The invention provides means and methods reducing or preventing the generation of HDEP. To this purpose, novel packaging cells and methods of making these are provided.Type: ApplicationFiled: March 20, 2006Publication date: August 17, 2006Inventors: Ronald Vogels, Menzo Havenga, David Adrianus Zuijdgeest
-
Patent number: 7037716Abstract: The invention provides improved methods and products based on adenoviral materials which can advantageously be used in gene therapy. In one aspect, an adenoviral vector is provided having no overlap with a suitable packaging cell line. The suitable packaging cell line is another aspect. The combination excludes the possibility of homologous recombination, thereby excluding the possibility of the formation of replication competent adenovirus. Another aspect embodies an adenovirus based helper construct which by its size is incapable of being encapsidated. This helper virus can be transferred into any suitable host cell making it a packaging cell. Furthermore, a number of useful mutations to adenoviral based materials and combinations of such mutations are disclosed, all of which have in common the safety of the methods and the products, in particular avoiding the production of replication competent adenovirus and/or interference with the immune system.Type: GrantFiled: March 25, 2003Date of Patent: May 2, 2006Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Publication number: 20060081016Abstract: A non-intrusive device for automatically dosing at least one liquid laundry care composition to an automatic laundry washing machine. The device employs a Venturi tube mechanism or a pump to dose the laundry detergent care composition. The dosing is controlled by a machine-generic algorithm capable of determining the actual cycle at any duration of wash for various cycle designs from various washing machines, without the input of precise cycle design; and dose the correct products correctly and is capable of distinguishing between major water addition and a water pulse.Type: ApplicationFiled: October 18, 2004Publication date: April 20, 2006Inventors: Feng-Lung Hsu, Sudhakar Puvvada, Ronald Vogel, Diane Wolf, Gary Hsu
-
Patent number: 7029848Abstract: Novel means and methods for their use are provided to determine the function of the product(s) of one or more sample nucleic acids. The sample nucleic acids are synthetic oligonucleotides, DNA, or cDNA and encode polypeptides, antisense nucleic acids, or GSEs. The sample nucleic acids are expressed in a host by a vehicle to alter at least one phenotype of the host. The altered phenotype(s) is/are identified as a means to assign a biological function to the product(s) encoded by the sample nucleic acid(s).Type: GrantFiled: December 21, 2001Date of Patent: April 18, 2006Assignee: Galapagos Genomics N.V.Inventors: Ronald Vogels, Abraham Bout, Helmuth van Es, Govert Schouten
-
Publication number: 20060014276Abstract: The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.Type: ApplicationFiled: August 18, 2005Publication date: January 19, 2006Inventors: Menzo Havenga, Ronald Vogels, Abraham Bout
-
Publication number: 20060004543Abstract: The installation of an electrical cable in a building and its subsequent testing are managed by first creating a computer database indicating the type of cable, the location where the cable is to be installed, the performance standard it should meet when installed in that location, and a test regimen to verify compliance with the performance standard. The database is then transferred into a hand held portable test instrument which is placed at the building site and connected to the cable to be tested.Type: ApplicationFiled: August 30, 2005Publication date: January 5, 2006Inventors: Ronald Vogel, Lee Watkins
-
Publication number: 20050288946Abstract: A business method for comprehensively planning the installation into a building of various dissimilar types of electrical cables. A feature of the method is that each individual cable, when installed in place, is then tested for the level of performance which will be required of that cable in that location.Type: ApplicationFiled: September 3, 2004Publication date: December 29, 2005Inventors: Ronald Vogel, Lee Watkins